In this issue of JAMA Oncology, Molinaro et al1 retrospectively assess the value of aggressive resection of glioblastoma (GBM) across molecular subtypes in a timely analysis. Both the large number of participants and the use of a significant development cohort and a multicenter validation cohort add strength to the findings.
Glioblastoma is the most common type of primary brain tumor and is also the most difficult to treat. Despite modern multimodal therapy including resection, radiotherapy, chemotherapy, and alternating electric fields, GBM remains one of the most aggressive and lethal cancers, with 5-year survival rates of less than 10%.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Choi BD, Gerstner ER, Curry WT. A Common Rule for Resection of Glioblastoma in the Molecular Era. JAMA Oncol. 2020;6(4):503–504. doi:10.1001/jamaoncol.2019.6384
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: